| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Day One Biopharmaceuticals Inc. Common Stock (NASDAQ: DAWN)
DAWN Technical Analysis
4
| As on 9th Jun 2023 DAWN STOCK Price closed @ 12.98 and we RECOMMEND Sell for LONG-TERM with Stoploss of 15.96 & Strong Sell for SHORT-TERM with Stoploss of 14.79 we also expect STOCK to react on Following IMPORTANT LEVELS. |
DAWNSTOCK Price
| Open | 13.30 | Change | Price | % |
| High | 13.81 | 1 Day | -0.25 | -1.89 |
| Low | 12.90 | 1 Week | 0.51 | 4.09 |
| Close | 12.98 | 1 Month | 1.24 | 10.56 |
| Volume | 1206400 | 1 Year | -4.87 | -27.28 |
| 52 Week High 26.57 | 52 Week Low 5.72 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| DAWN Daily Charts |
DAWN Intraday Charts |
Whats New @ Bazaartrend |
DAWN Free Analysis |
|
|
DAWN Important Levels Intraday
| RESISTANCE | 14.73 |
| RESISTANCE | 14.17 |
| RESISTANCE | 13.82 |
| RESISTANCE | 13.48 |
| SUPPORT | 12.48 |
| SUPPORT | 12.14 |
| SUPPORT | 11.79 |
| SUPPORT | 11.23 |
DAWN Forecast April 2024
| 4th UP Forecast | 22.62 |
| 3rd UP Forecast | 19.53 |
| 2nd UP Forecast | 17.62 |
| 1st UP Forecast | 15.71 |
| 1st DOWN Forecast | 10.26 |
| 2nd DOWN Forecast | 8.35 |
| 3rd DOWN Forecast | 6.44 |
| 4th DOWN Forecast | 3.35 |
DAWN Weekly Forecast
| 4th UP Forecast | 18.13 |
| 3rd UP Forecast | 16.48 |
| 2nd UP Forecast | 15.46 |
| 1st UP Forecast | 14.44 |
| 1st DOWN Forecast | 11.52 |
| 2nd DOWN Forecast | 10.50 |
| 3rd DOWN Forecast | 9.48 |
| 4th DOWN Forecast | 7.83 |
DAWN Forecast2024
| 4th UP Forecast | 57.13 |
| 3rd UP Forecast | 42.97 |
| 2nd UP Forecast | 34.22 |
| 1st UP Forecast | 25.47 |
| 1st DOWN Forecast | 0.49 |
| 2nd DOWN Forecast | -8.26 |
| 3rd DOWN Forecast | -17.01 |
| 4th DOWN Forecast | -31.17 |
Day One Biopharmaceuticals Inc. Common Stock ( NASDAQ USA Symbol : DAWN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
DAWN Business Profile
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Address: 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080-1930
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service